Neurovance is a clinical stage neuroscience-focused company. We are working to develop a novel approach to help adults and children with ADHD, Attention Deficit Hyperactivity Disorder
Hypothesis-driven, proprietary research at Neurovance discovered and developed centanafadine (CTN), a triple reuptake inhibitor that modulates the activity of norepinephrine dopamine and serotonin in a specific ratio.
OUR FINDINGS TO-DATE
Initial studies have demonstrated CTN has efficacy approaching that of stimulants to treat ADHD, but with reduced potential for abuse compared to two leading stimulant-type medications frequently prescribed for adult ADHD